{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-267185","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2022-10-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.242226+00:00","generated_at":"2026-06-23T01:38:42.104203+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acumen's ACU193 receives FDA Fast Track designation for early Alzheimer's disease","bullets":["ACU193 is first clinical-stage monoclonal antibody selectively targeting toxic soluble amyloid beta oligomers (AßOs).","Phase 1 INTERCEPT-AD trial ongoing to assess safety and proof of mechanism.","Fast Track facilitates more frequent FDA engagement to expedite development and review.","ACU193's unique binding profile may offer low risk of ARIA by avoiding direct plaque targeting.","CEO Daniel O'Connell cites potential clinical utility and collaboration with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-267185","json":"https://secwatch.observer/filing/0001193125-22-267185.json","markdown":"https://secwatch.observer/filing/0001193125-22-267185.md","text":"https://secwatch.observer/filing/0001193125-22-267185.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522267185/0001193125-22-267185-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312522267185/d358925d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:38:42.104203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}